TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33021670

Group type: EXPERIMENTAL
Intervention: CI-specific, home-based strength, balance, and walking training supported by tailored motivational strategies
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo activity
Number of subjects: 118
Study: 35631156

Group type: EXPERIMENTAL
Intervention: GTB1 (Lactiplantibacillus plantarum APsulloc 331261)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 33736993

Group type: EXPERIMENTAL
Intervention: Modified natural cycle FET (NC-FET)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Artificial cycle FET (AC-FET)
Number of subjects: 98
Study: 36026477

Group type: EXPERIMENTAL
Intervention: Refined maize porridge with [57Fe]-labeled crickets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Refined maize porridge with unlabeled crickets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference meal (refined maize porridge with [58Fe]SO4)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unrefined maize porridge with crickets
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Unrefined maize porridge with [54Fe]SO4
Number of subjects: 20
Study: 34551218

Group type: EXPERIMENTAL
Intervention: RBP‐7000 90 mg
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: RBP‐7000 120 mg
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 35579143

Group type: EXPERIMENTAL
Intervention: Low dose dobutamine (infusion rates of 5, 10, 15, and 20 μg/kg/min)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 186
Study: 35914297

Group type: EXPERIMENTAL
Intervention: Lotilaner ophthalmic solution, 0.25%
Number of subjects: 54

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 54
Study: 33201041

Group type: EXPERIMENTAL
Intervention: 3D‐MOT training
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 2048 game
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 62
Study: 33036661

Group type: EXPERIMENTAL
Intervention: IMPACT (Instant MSC Product accompanying Autologous Chondron Transplantation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IMPACT
Number of subjects: 60
Study: 35239009

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 700
Study: 34000494

Group type: EXPERIMENTAL
Intervention: Video intervention administered at the time of the universal newborn hearing screen
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study: 32216109

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg MTX administered subcutaneously once per week for 3 months
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg MTX administered subcutaneously
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg week−1 MTX (suggested dose)
Number of subjects: 6
Study: 35917136

Group type: EXPERIMENTAL
Intervention: Remote access control software (phase 3)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Phone assistance from investigators (phase 1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Local Lions Club volunteers (phase 2)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Telerehabilitation (phase 3)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Telerehabilitation (all phases)
Number of subjects: 55
Study: 33766001

Group type: EXPERIMENTAL
Intervention: Training package for healthcare professionals
Number of subjects: 35
Study: 32348166

Group type: EXPERIMENTAL
Intervention: ARBs/ACEIs
Number of subjects: 126

Group type: COMPARATOR
Intervention: non-ARBs/ACEIs
Number of subjects: 126
Study: 35106719

Group type: EXPERIMENTAL
Intervention: Telepsychiatry Collaborative Care (TCC)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Telepsychiatry/Telepsychology Enhanced Referral (TER)
Number of subjects: 1004
Study: 34896445

Group type: EXPERIMENTAL
Intervention: Nanocort 75 mg i.v. infusion plus i.m. saline injection
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nanocort 150 mg i.v. infusion plus i.m. saline injection
Number of subjects: 150

Group type: COMPARATOR
Intervention: Depo‐Medrol® 120 mg i.m. injection plus i.v. saline infusion
Number of subjects: 150
Study: 33358625

Group type: EXPERIMENTAL
Intervention: Mitral calcification at 24 months
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Aortic calcification at 24 months
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Valvular calcification prevalence
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Two-year progression of calcification
Number of subjects: 397
Study: 32807165

Group type: EXPERIMENTAL
Intervention: Fortified whey beverage (250 ml daily for 8 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 36088785

Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min per day, 2 mA, 2 weeks duration)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intensified tDCS (2 × 20 min per day, 2 mA, 2 weeks duration)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned in the abstract)
Number of subjects: 19
Study: 36293555

Group type: EXPERIMENTAL
Intervention: Xanthohumol (XN) derived from a XN-rich hop extract (75% XN), 0.125 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Xanthohumol (XN) derived from a XN-rich hop extract (75% XN)
Number of subjects: 9
Study: 33113155

Group type: EXPERIMENTAL
Intervention: GSK2831781 (5 mg/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: GSK2831781 (0.5, 1.5, and 5 mg/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 34727281

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard Nasal Cannula
Number of subjects: 187
Study: 34259466

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg orally, followed by a repeat dose after 90 minutes if contractions persisted, continued every 4 hours for 48 hours.
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 32770983

Group type: EXPERIMENTAL
Intervention: Back in the Game smartphone application intervention (24-week Internet-delivered programme based on cognitive-behavioural therapy)
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Usual rehabilitation care plus Back in the Game smartphone application
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual rehabilitation care alone
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Back in the Game smartphone application intervention
Number of subjects: 222
Study: 35477496

Group type: EXPERIMENTAL
Intervention: 3 g of probiotic preparation for 4 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 5 g of prebiotic (organic oat bran) supplementation for 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: 3 g of probiotic preparation or 5 g of prebiotic supplementation
Number of subjects: 43
Study: 33203440

Group type: EXPERIMENTAL
Intervention: Online EMDR (R-TEP) intervention with a maximum of eight weekly sessions delivered by a trained psychological therapist.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Standard care plus online EMDR (R-TEP) intervention.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard care (control).
Number of subjects: 26
Study: 33334933

Group type: EXPERIMENTAL
Intervention: Proteomic biomarker panel (8 proteins)
Number of subjects: 157
Study: 35237788

Group type: EXPERIMENTAL
Intervention: Hydrosurgical debridement
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional debridement
Number of subjects: 137
Study: 32895647

Group type: EXPERIMENTAL
Intervention: Herbal-based oral rinse
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine-based oral rinse
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-surgical mechanical debridement only
Number of subjects: 48
Study: 36066248

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with SMART goals set by children over six months
Number of subjects: 0
Study: 33631291

Group type: EXPERIMENTAL
Intervention: NSE at 48 hours
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: S-100b and NSE biomarkers
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 79
Study: 32393479

Group type: EXPERIMENTAL
Intervention: Orthèse Diabète (experimental device)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Conventional removable offloading devices (control group)
Number of subjects: 112
Study: 34998371

Group type: EXPERIMENTAL
Intervention: Norepinephrine (3.2 μg/min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phenylephrine (40 μg/min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 100
Study: 34519194

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (NSE)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: NSE with a behavioral approach (NSEB)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Prescribed physical activity (PPA)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: NSE and NSEB
Number of subjects: 216
Study: 32731978

Group type: EXPERIMENTAL
Intervention: Corn sample 1
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Corn sample 2
Number of subjects: 54
Study: 35103603

Group type: EXPERIMENTAL
Intervention: Trial organized according to patient preferences (hybrid model with both on-site and remote visits)
Number of subjects: 628

Group type: COMPARATOR
Intervention: Trial organized in a non-preferred model (not specified)
Number of subjects: 628
Study: 32124409

Group type: EXPERIMENTAL
Intervention: TAU + BPT
Number of subjects: 182

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 182
Study: 35405661

Group type: EXPERIMENTAL
Intervention: Coping Support Intervention (CSI)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 152
Study: 32476057

Group type: EXPERIMENTAL
Intervention: Current employment at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted cumulative effect of employment over 8 follow-up visits
Number of subjects: 0
Study: 33298663

Group type: EXPERIMENTAL
Intervention: J-DASH 1 diet 1×/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: J-DASH 2 diet providing fish hamburger-patty 2×/day (5 days/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 40
Study: 34686168

Group type: EXPERIMENTAL
Intervention: Stainless Steel (SS) ligatures
Number of subjects: 70

Group type: COMPARATOR
Intervention: Elastomeric (EM) ligatures
Number of subjects: 70
Study: 32900361

Group type: EXPERIMENTAL
Intervention: Tramadol (1-2 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fentanyl (1 μg/kg-i.v.)
Number of subjects: 120
Study: 34133087

Group type: EXPERIMENTAL
Intervention: Prolonged exposure plus sertraline (PE + SERT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Prolonged exposure plus placebo (PE + PLB)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management (SERT + EMM)
Number of subjects: 196
Study: 32006009

Group type: EXPERIMENTAL
Intervention: Iron-biofortified beans (Fe-Bean; 86.1 mg Fe/kg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional beans (control: 50.6 mg Fe/kg)
Number of subjects: 125
Study: 35871951

Group type: EXPERIMENTAL
Intervention: Standard-of-care (SOC) + Teduglutide (TED) for 2 months
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quality of life survey
Number of subjects: 6
Study: 33621970

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification for Appraisals (CBM‐APP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 80
Study: 36150304

Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy
Number of subjects: 8
Study: 33545972

Group type: EXPERIMENTAL
Intervention: liraglutide once daily (blinded) combined with glimepiride and metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: liraglutide placebo once daily (blinded) combined with glimepiride and metformin
Number of subjects: 0
Study: 32874044

Group type: EXPERIMENTAL
Intervention: Nylon sutures
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 50
Study: 35882823

Group type: COMPARATOR
Intervention: Conventional-dose Bacillus coagulans TBC169
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose Bacillus coagulans TBC169
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo-control
Number of subjects: 0
Study: 34571044

Group type: EXPERIMENTAL
Intervention: Emtricitabine and tenofovir alafenamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emtricitabine and tenofovir disoproxil fumarate
Number of subjects: 0
Study: 33730206

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise and neck-specific exercise (AE group)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Neck-specific exercise alone (control group)
Number of subjects: 139
Study: 32949267

Group type: EXPERIMENTAL
Intervention: SB8 (bevacizumab biosimilar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: bevacizumab‐EU
Number of subjects: 0

Group type: COMPARATOR
Intervention: bevacizumab‐US
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SB8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SB8, bevacizumab‐EU, bevacizumab‐US
Number of subjects: 0
Study: 35986664

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly (qw)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks (q2w)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 4 weeks (q4w)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg every 4 weeks (q4w)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study: 34032604

Group type: EXPERIMENTAL
Intervention: Treatment at sites with the highest intubation rate
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: 20-minute neurologic recovery
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: 60-minute neurologic recovery
Number of subjects: 478

Group type: COMPARATOR
Intervention: Baseline characteristics including seizure precipitant, benzodiazepine dosing, and admission vital signs
Number of subjects: 478
Study: 32279184

Group type: EXPERIMENTAL
Intervention: Video-assisted informed consent (additional informing video presentation)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual verbal-written informed consent
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Video-assisted informed consent
Number of subjects: 74
Study: 35164796

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 11617
Study: 34335455

Group type: EXPERIMENTAL
Intervention: Inhibitory repetitive Transcranial Magnetic Stimulation (i-rTMS) followed by cognitive treatment for 15 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: SHAM control
Number of subjects: 0
Study: 36243386

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg inhaled
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 μg inhaled
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg twice daily (BID)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 μg BID
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 250 μg BID
Number of subjects: 85

Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 100, 200, 400 μg once daily (QD)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 μg BID
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000 μg BID
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 800 μg QD
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 644 μg/day
Number of subjects: 85
Study: 32989770

Group type: EXPERIMENTAL
Intervention: Hand-sewn end-to-end anastomosis (ETE)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Semi-mechanical anastomosis (SMA)
Number of subjects: 174
Study: 37073443

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study: 35073398

Group type: EXPERIMENTAL
Intervention: Mixture of six HLA-DRB1*0401-selective, β-cell peptides administered intradermally at doses of 10, 100, and 500 μg for 24 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixture of six HLA-DRB1*0401-selective, β-cell peptides
Number of subjects: 0
Study: 34379856

Group type: EXPERIMENTAL
Intervention: RMGI‐F varnish
Number of subjects: 74

Group type: COMPARATOR
Intervention: GI sealant (active control)
Number of subjects: 74
Study: 33618181

Group type: EXPERIMENTAL
Intervention: Dexamethasone (25 nM for 24 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypoxia (4% O2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MNRR1 knockout cells
Number of subjects: 0
Study: 32736583

Group type: EXPERIMENTAL
Intervention: eCREST (electronic Clinical Reasoning Educational Simulation Tool) - intervention group received three patient cases.
Number of subjects: 264

Group type: COMPARATOR
Intervention: Teaching as usual - control group.
Number of subjects: 264
Study: 33987556

Group type: EXPERIMENTAL
Intervention: Home-based contraceptive delivery (condoms, pills, injection, implant) during routine 40-day postpartum visit
Number of subjects: 208

Group type: COMPARATOR
Intervention: Routine care alone (comprehensive contraceptive counseling throughout antepartum care)
Number of subjects: 208
Study: 32554690

Group type: EXPERIMENTAL
Intervention: Slimpod® intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Audio relaxation (control)
Number of subjects: 82
Study: 35945570

Group type: EXPERIMENTAL
Intervention: WhatsApp Messenger educational videos (twice a week) + conventional oral health education (single visit)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional oral health education (single visit)
Number of subjects: 100
Study: 34455171

Group type: EXPERIMENTAL
Intervention: Grip training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 33325344

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (Group 3)
Number of subjects: 155

Group type: COMPARATOR
Intervention: No postoperative antibiotics (Group 1)
Number of subjects: 155

Group type: COMPARATOR
Intervention: No postoperative antibiotics (Group 2)
Number of subjects: 155
Study: 35950355

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Supragingival scaling with vitamin C
Number of subjects: 89

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 89
Study: 33441099

Group type: EXPERIMENTAL
Intervention: Strength exercise (2 circuits of resistance exercise: 6 exercises with 10 repetitions at 65-70% of one repetition maximum)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endurance exercise (30 minutes running at 65-70% of maximal heart rate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 32931457

Group type: EXPERIMENTAL
Intervention: Yoga-based relaxation technique (YBRT) practiced 1 hour a day for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group maintaining usual physical activity regimen
Number of subjects: 22
Study: 36031616

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 81
Study: 32046765

Group type: EXPERIMENTAL
Intervention: TAU plus IPS (experimental condition)
Number of subjects: 832

Group type: COMPARATOR
Intervention: TAU (control condition)
Number of subjects: 832
Study: 36261422

Group type: EXPERIMENTAL
Intervention: Elated mental imagery condition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Calm mental imagery condition
Number of subjects: 61
Study: 34239940

Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional oral antihyperglycemic drugs (OADs)
Number of subjects: 70
Study: 33078388

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 2749

Group type: COMPARATOR
Intervention: Opioids
Number of subjects: 2749

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 2749

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 2749
Study: 36775516

Group type: EXPERIMENTAL
Intervention: Swedish Massage Therapy (SMT) for 12 weeks
Number of subjects: 47

Group type: COMPARATOR
Intervention: Swedish Massage Therapy (SMT) for 6 weeks followed by 6 weeks of light touch (LT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Swedish Massage Therapy (SMT)
Number of subjects: 47
Study: 33385318

Group type: COMPARATOR
Intervention: Reference formulation of dapoxetine hydrochloride
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Test formulation of dapoxetine hydrochloride
Number of subjects: 80
Study: 32017646

Group type: EXPERIMENTAL
Intervention: Drinkable collagen supplement containing special collagen peptides, acerola extract, vitamin C, vitamin E, biotin, and zinc for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Drinkable collagen supplement
Number of subjects: 60
Study: 34293034

Group type: EXPERIMENTAL
Intervention: Peer Video Feedback (PVF)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard Instructor Feedback (SIF)
Number of subjects: 288
Study: 35814411

Group type: EXPERIMENTAL
Intervention: Proximal gastrectomy plus jejunal interposition (PG+JI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Proximal gastrectomy plus esophagogastrostomy (PG+EG)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total gastrectomy plus Roux‐en‐Y esophagojejunostomy (TG+RY)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100